Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

The Optimal Initiation Timing for Cyclosporine in Allogeneic Transplantation, Earlier Is Better with the Price of Higher Rate of Chronic Gvhd.

Liliane Dray, Aliza Matusevich, Igor Resnick, Memet Aker, M.D, Simcha Samuel, Reuven Or, Michael Y. Shapira, MD

Blood (2009) 114 (22): 1143.

https://doi.org/10.1182/blood.V114.22.1143.1143

Published: 2009

Journal Articles

The Rate of Cytomegalovirus Infection and Disease in Correlation with the Type of Hematopoietic Stem Cell Transplantation in the Era of Preemptive Antiviral Therapy

Benjamin Gesundheit, Reuven Or, Einat Budowski, Michael Y. Shapira, MD, Igor B. Resnick, Simcha Samuel, Liliane Dray, Orit Kaplan, Dana Wolf

Blood (2008) 112 (11): 4347.

https://doi.org/10.1182/blood.V112.11.4347.4347

Published: 2008

Journal Articles

Simultaneous Haploidentically Mismatched Stem Cell Transplantation from Multi-Donors (MDT) in Humans Offers Better Engraftment as Compared to Single Haploidentical Donor.

Michael Y. Shapira, MD, Igor B. Resnick, MD DSc PhD, Benjamin Gesundeheidt, MD PhD, Simcha Samuel, MSc, Liliane Drey, RN, Yuri Verkholevsky, RN BA, Shimon Slavin, MD, Reuven Or, MD

Blood (2007) 110 (11): 4854.

https://doi.org/10.1182/blood.V110.11.4854.4854

Published: 2007

Journal Articles

Thymoglobulin ® Rabbit Anti-Thymocyte Globulins (r-ATG) Induces Faster Platelet Recovery and Does Not Suppress Granulocyte Engraftment in a Non-Myeloablative Stem Cell Transplantation Setting.

Michael Y. Shapira, MD, Igor B. Resnick, MD PhD DSc, Benjamin Gesundeheidt, MD PhD, Menachem Bitan, Aliza Ackerstein, MSc, Simcha Samuel, MSc, Liliane Drey, RN BA, Yuri Verkholevsky, RN BA, Shimon Slavin, MD, Reuven Or, MD

Blood (2007) 110 (11): 4942.

https://doi.org/10.1182/blood.V110.11.4942.4942

Published: 2007

Journal Articles

Assessment of the Immune Reconstitution by Cylex Immuknow™ Assay in Patients after Allogeneic Stem Cell Transplantation.

Benjamin Gesundheit, MD, PhD, Yehudit Azar, PhD, Rachel Bringer, BSc, Schivti Steinberg-Prop, MSc, Moshe Israeli, BSc, Michael Y. Shapira, MD, Igor Resnick, MD, Simcha Samuel, MSc, Shimon Slavin, MD, Reuven Or, MD

Blood (2006) 108 (11): 3219.

https://doi.org/10.1182/blood.V108.11.3219.3219

Published: 2006

Journal Articles

Enhancement of Hematopoietic Stem Cell Engraftment and Graft vs. Leukemia Effect Induced by Matched and Haploidentically Mismatched Allograft Using Multi-Donor Stem Cell Transplantation (MDT).

Michael Y. Shapira, MD, Reuven Or, MD, Igor B. Resnick, MD PhD, Simcha Samuel, MSc, Benjamin Gesundheit, MD PhD, Shimon Slavin, MD

Blood (2006) 108 (11): 3663.

https://doi.org/10.1182/blood.V108.11.3663.3663

Published: 2006

Journal Articles

Amplification of Graft vs Malignancy (GVM) Effects by Using Intentionally Mismatched Donor Lymphocytes While Avoiding Graft-vs-Host Disease in Conjunction with Haploidentically Mismatched Stem Cell Allografts in Patients with Hematological Malignances.

Shimon Slavin, MD, Michael Y. Shapira, MD, Igor B. Resnick, MD, Menachem Bitan, MD, Memet Aker, MD, Simcha Samuel, MSc, Shoshana Morecki, PhD, Reuven Or, MD

Blood (2006) 108 (11): 5157.

https://doi.org/10.1182/blood.V108.11.5157.5157

Published: 2006

Journal Articles

Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation.

Menachem Bitan, MD, Michael Y. Shapira, MD, Igor B. Resnick, MD, Benjamin Gesundheit, MD, Irena Zilberman, MD, Aliza Ackerstein, M.Sc, Simcha Samuel, M.Sc, Sharon Elad, DMD, Shimon Slavin, MD, Reuven Or, MD

Blood (2005) 106 (11): 5326.

https://doi.org/10.1182/blood.V106.11.5326.5326

Published: 2005

Journal Articles

Effective Treatment of Resistant Hematological Malignancies by IL-2 Activated NK Cells Using Haploidentically Mismatched Donors by Induction of Graft-Versus-Tumor (GVT) Effect While Avoiding GVHD.

Shimon Slavin, MD, Reuven Or, MD, Aliza Ackerstein, MSc, Simcha Samuel, MSc, Michael Y. Shapira, MD, Igor Resnick, MD, Menachem Bitan, MD, Memet Aker, MD, Yael Gelfand, MSc, Osnat Eizik, Shoshana Morecki, PhD

Blood (2005) 106 (11): 5400.

https://doi.org/10.1182/blood.V106.11.5400.5400

Published: 2005

Journal Articles

20 Years of Experience with Hematopoietic Stem Cell Transplantation for β-Thalassemia Major.

Benjamin Gesundheit, MD, PhD, Mamet Aker, MD, Igor Resnick, MD, Michael Y. Shapira, MD, Menachem Bitan, MD, Simcha Samuel, MSC, Shimon Slavin, MD, Reuven Or, MD

Blood (2005) 106 (11): 3657.

https://doi.org/10.1182/blood.V106.11.3657.3657

Published: 2005

Journal Articles

Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD.

Shimon Slavin, MD, Reuven Or, MD, Memet Aker, MD, Michael Y. Shapira, MD, Igor B. Resnick, MD, Menachem Bitan, MD, Svetlana Miron, MD, Irina Zilberman, MD, Simcha Samuel, MSc, Yael Gelfand, MSc, Corinne Nabet, Osnat Isaacs, Aliza Ackerstein, MSc, Shoshana Morecki, PhD

Blood (2004) 104 (11): 5180.

https://doi.org/10.1182/blood.V104.11.5180.5180

Published: 2004

Journal Articles

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

Reuven Or, Michael Y. Shapira, Igor Resnick, Avraham Amar, Aliza Ackerstein, Simcha Samuel, Memet Aker, Elizabeth Naparstek, Arnon Nagler, Shimon Slavin

Blood (2003) 101 (2): 441–445.

https://doi.org/10.1182/blood-2002-02-0535

Published: 2003

Journal Articles

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

Shimon Slavin, Arnon Nagler, Ella Naparstek, Yossi Kapelushnik, Memet Aker, Gabriel Cividalli, Gabor Varadi, Mark Kirschbaum, Aliza Ackerstein, Simcha Samuel, Avraham Amar, Chaim Brautbar, Ofira Ben-Tal, Amiram Eldor, Reuven Or

Blood (1998) 91 (3): 756–763.

https://doi.org/10.1182/blood.V91.3.756

Published: 1998

NARROW

The Optimal Initiation Timing for Cyclosporine in Allogeneic Transplantation, Earlier Is Better with the Price of Higher Rate of Chronic Gvhd.

The Rate of Cytomegalovirus Infection and Disease in Correlation with the Type of Hematopoietic Stem Cell Transplantation in the Era of Preemptive Antiviral Therapy

Simultaneous Haploidentically Mismatched Stem Cell Transplantation from Multi-Donors (MDT) in Humans Offers Better Engraftment as Compared to Single Haploidentical Donor.

Thymoglobulin ® Rabbit Anti-Thymocyte Globulins (r-ATG) Induces Faster Platelet Recovery and Does Not Suppress Granulocyte Engraftment in a Non-Myeloablative Stem Cell Transplantation Setting.

Assessment of the Immune Reconstitution by Cylex Immuknow™ Assay in Patients after Allogeneic Stem Cell Transplantation.

Enhancement of Hematopoietic Stem Cell Engraftment and Graft vs. Leukemia Effect Induced by Matched and Haploidentically Mismatched Allograft Using Multi-Donor Stem Cell Transplantation (MDT).

Amplification of Graft vs Malignancy (GVM) Effects by Using Intentionally Mismatched Donor Lymphocytes While Avoiding Graft-vs-Host Disease in Conjunction with Haploidentically Mismatched Stem Cell Allografts in Patients with Hematological Malignances.

Duration to Engraftment Requires Significantly Much More Time in Myelodysplastic Syndrome (MDS) Patients as Compared to Acute Myeloid Leukemia (AML) Patients Following Allogeneic Stem Cell Transplantation.

Effective Treatment of Resistant Hematological Malignancies by IL-2 Activated NK Cells Using Haploidentically Mismatched Donors by Induction of Graft-Versus-Tumor (GVT) Effect While Avoiding GVHD.

20 Years of Experience with Hematopoietic Stem Cell Transplantation for β-Thalassemia Major.

Treatment of Resistant Leukemia by rIL-2 Activated NK Cells in Recipients of HLA Matched and Haploidentically Mismatched Stem Cell Allografts while Avoiding GVHD.

Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase

Nonmyeloablative Stem Cell Transplantation and Cell Therapy as an Alternative to Conventional Bone Marrow Transplantation With Lethal Cytoreduction for the Treatment of Malignant and Nonmalignant Hematologic Diseases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only